Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Recruiting
Phase 4
Interventional Study
Post Operative Pulmonary Complications
Neuromuscular Blockade
General Anesthesia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 490 (estimated)
- Sponsor
- The University of Texas Medical Branch, Galveston · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* The subject is able and willing to provide and sign informed consent
* The subject must be between 18 and 80 years of age
* The subject should have chronic kidney disease as defined by glomerular filtration rate
* The surgery must require general anesthesia with endotracheal i…
Contacts